Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
Sana Biotechnology (NASDAQ: SANA), a company specializing in engineered cells for patient treatment, has announced its participation in the Goldman Sachs Cell Therapy Day Conference. The event will take place on Tuesday, October 1, 2024, with Sana's panel scheduled for 1:00 p.m. ET.
Steve Harr, Sana's President and CEO, will present a business overview and update during the panel. The presentation will be webcast live and accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of the presentation will remain available on the website for 30 days following the conference.
This participation provides an opportunity for investors and interested parties to gain insights into Sana Biotechnology's current operations and future plans in the field of engineered cell therapies.
Sana Biotechnology (NASDAQ: SANA), un'azienda specializzata in cellule ingegnerizzate per il trattamento dei pazienti, ha annunciato la sua partecipazione alla Goldman Sachs Cell Therapy Day Conference. L'evento si terrà Martedì, 1 ottobre 2024, con il panel di Sana programmato per le 13:00 ET.
Steve Harr, Presidente e CEO di Sana, presenterà una panoramica aziendale e un aggiornamento durante il panel. La presentazione sarà trasmessa in diretta e accessibile sulla pagina delle Relazioni con gli Investitori del sito web di Sana all'indirizzo https://sana.com/. Una registrazione della presentazione sarà disponibile sul sito per 30 giorni dopo la conferenza.
Questa partecipazione offre un'opportunità agli investitori e ai soggetti interessati di ottenere approfondimenti sulle attuali operazioni di Sana Biotechnology e sui piani futuri nel campo delle terapie cellulari ingegnerizzate.
Sana Biotechnology (NASDAQ: SANA), una empresa especializada en células diseñadas para el tratamiento de pacientes, ha anunciado su participación en la Goldman Sachs Cell Therapy Day Conference. El evento se llevará a cabo el martes, 1 de octubre de 2024, con el panel de Sana programado para las 1:00 p.m. ET.
Steve Harr, presidente y CEO de Sana, presentará una visión general del negocio y una actualización durante el panel. La presentación será transmitida en vivo y accesible en la página de Relaciones con Inversores del sitio web de Sana en https://sana.com/. Una repetición de la presentación estará disponible en el sitio durante 30 días después de la conferencia.
Esta participación brinda una oportunidad para que los inversores y partes interesadas obtengan información sobre las operaciones actuales de Sana Biotechnology y sus planes futuros en el campo de las terapias celulares diseñadas.
사나 생명공학(Sana Biotechnology) (NASDAQ: SANA), 환자 치료를 위한 공학 세포에 특화된 회사가 골드만 삭스 세포 치료의 날 회의(Goldman Sachs Cell Therapy Day Conference)에 참여한다고 발표했습니다. 이 행사는 2024년 10월 1일 화요일에 열리며, 사나의 패널은 동부 표준시 오후 1시로 예정되어 있습니다.
스티브 해리(Steve Harr), 사나의 사장 겸 CEO는 패널에서 사업 개요와 업데이트를 발표할 예정입니다. 발표는 실시간으로 방송될 것이며, 사나 웹사이트의 투자자 관계 페이지(https://sana.com/)에서 접근 가능합니다. 발표의 재상영은 회의 후 30일 동안 웹사이트에서 제공됩니다.
이 참여는 투자자와 관심 있는 당사자들에게 사나 생명공학의 현재 운영 및 공학 세포 치료 분야의 미래 계획에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Sana Biotechnology (NASDAQ: SANA), une entreprise spécialisée dans les cellules ingénierées pour le traitement des patients, a annoncé sa participation à la Goldman Sachs Cell Therapy Day Conference. L'événement aura lieu le mardi 1er octobre 2024, avec un panel de Sana prévu à 13h00 ET.
Steve Harr, le président et CEO de Sana, présentera un aperçu commercial et une mise à jour durant le panel. La présentation sera diffusée en direct et accessible sur la page Relations Investisseurs du site internet de Sana à l'adresse https://sana.com/. Un enregistrement de la présentation restera disponible sur le site pendant 30 jours après la conférence.
Cette participation représente une occasion pour les investisseurs et les parties intéressées d'acquérir des informations sur les opérations actuelles de Sana Biotechnology et ses plans futurs dans le domaine des thérapies cellulaires ingénieures.
Sana Biotechnology (NASDAQ: SANA), ein Unternehmen, das sich auf gezielte Zellen zur Behandlung von Patienten spezialisiert hat, hat seine Teilnahme an der Goldman Sachs Cell Therapy Day Conference angekündigt. Die Veranstaltung findet am Dienstag, den 1. Oktober 2024 statt, mit Sanas Panel, das für 13:00 Uhr ET geplant ist.
Steve Harr, Präsident und CEO von Sana, wird während des Panels einen Geschäftsüberblick und ein Update präsentieren. Die Präsentation wird live übertragen und kann auf der Investor-Relations-Seite von Sanas Webseite unter https://sana.com/ abgerufen werden. Eine Wiederholung der Präsentation wird für 30 Tage nach der Konferenz auf der Webseite verfügbar sein.
Diese Teilnahme bietet Investoren und interessierten Parteien die Gelegenheit, Einblicke in die aktuellen Aktivitäten von Sana Biotechnology und die zukünftigen Pläne im Bereich der gezielten Zelltherapien zu erhalten.
- None.
- None.
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its panel at the Goldman Sachs Cell Therapy Day Conference at 1:00 p.m. ET on Tuesday, October 1, 2024. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.
The webcast will be accessible on the Investor Relations page of Sana’s website at https://sana.com/. A replay of the presentation will be available at the same location for 30
days following the conference.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA, Bothell, WA and Rochester, NY. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision; the Company’s participation at the Goldman Sachs Cell Therapy Day Conference; and the subject matter of the Company’s panel at the
conference. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-Q dated August 8, 2024. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
FAQ
When is Sana Biotechnology (SANA) presenting at the Goldman Sachs Cell Therapy Day Conference?
Who will be presenting for Sana Biotechnology (SANA) at the Goldman Sachs conference?
How can I access Sana Biotechnology's (SANA) presentation at the Goldman Sachs conference?
How long will the replay of Sana Biotechnology's (SANA) presentation be available?
